Liver Fetuin-A at Initiation of Insulin Resistance.

Kupffer cell fatty liver fetuin-A hepatokine immunofluorescence insulin resistance macrophage nonalcoholic fatty liver disease prediabetes steatosis

Journal

Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790

Informations de publication

Date de publication:
25 Oct 2022
Historique:
received: 13 09 2022
revised: 18 10 2022
accepted: 22 10 2022
entrez: 10 11 2022
pubmed: 11 11 2022
medline: 11 11 2022
Statut: epublish

Résumé

Hepatokines (liver secreted proteins with possible distant action) are emerging potential players in insulin resistance in type 2 diabetic patients. Here, we explored the effect of a high-fat diet on the expression of fetuin-A, one of those candidate liver proteins, and its relationship with liver macrophage activation. Mice were fed a normal diet or a high-fat diet for 3 days, known to initiate steatosis and liver insulin resistance. A preventive liver macrophage depletion was obtained by intravenous injection of clodronate-loaded liposomes. The mRNA and protein expression of fetuin-A was evaluated by qPCR, Western blot and immunofluorescence on different insulin-sensitive tissues (liver, adipose tissue, and muscle). Short-term high-fat diet-induced steatosis, liver macrophage activation, and hepatic insulin resistance together with a significantly increased expression of liver AHSG (α2-HS glycoprotein/fetuin-A) mRNA and serum fetuin-A concentration. On immunofluorescence, fetuin-A was mostly expressed in centrilobular hepatocytes. This increase in fetuin-A under high-fat diet was not evidenced in other peripheral insulin-sensitive tissues (skeletal muscle and adipose tissue). The mRNA expression of α2-HS glycoprotein was 800 times higher within the liver compared with the adipose tissue or the muscle. Liver macrophage depletion that significantly ameliorated insulin sensitivity was associated with a significant decrease in α2-HS glycoprotein mRNA expression. In conclusion, this study demonstrated liver fetuin-A overexpression at the initiation of high-fat diet feeding, concurrent with hepatic steatosis and insulin resistance. Targeting liver macrophages in this setting reduced liver α2-HS glycoprotein expression suggesting that fetuin-A acts as an hepatokine with proinsulin resistance effects.

Identifiants

pubmed: 36355106
pii: metabo12111023
doi: 10.3390/metabo12111023
pmc: PMC9693222
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : UCLouvain
ID : Starting grant
Organisme : Fund for Scientific Research
ID : FRS-FNRS Belgium

Références

Clin Sci (Lond). 2013 Dec;125(11):501-11
pubmed: 23758436
Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):27-38
pubmed: 17690317
Medicine (Baltimore). 2015 Sep;94(39):e1517
pubmed: 26426614
World J Gastroenterol. 2020 Apr 28;26(16):1861-1878
pubmed: 32390698
Biomedicines. 2021 Dec 14;9(12):
pubmed: 34944728
Proc Natl Acad Sci U S A. 1981 Aug;78(8):4970-4
pubmed: 7029527
BMJ Open. 2021 Aug 25;11(8):e045498
pubmed: 34433590
Diabetes Care. 2006 Feb;29(2):468
pubmed: 16443916
PLoS One. 2011 Apr 27;6(4):e19228
pubmed: 21556362
Lancet Gastroenterol Hepatol. 2022 May;7(5):388-390
pubmed: 35248211
Acta Gastroenterol Belg. 2022 Apr-Jun;85(2):346-357
pubmed: 35709779
Endocr Rev. 2019 Oct 1;40(5):1367-1393
pubmed: 31098621
Lab Invest. 2007 Jan;87(1):56-65
pubmed: 17075577
Diabetes Care. 2006 Apr;29(4):853-7
pubmed: 16567827
World J Hepatol. 2020 Dec 27;12(12):1168-1181
pubmed: 33442446
Nat Med. 2005 Feb;11(2):183-90
pubmed: 15685173
JHEP Rep. 2019 Feb 23;1(1):30-43
pubmed: 32149275
Metabolites. 2022 Jul 07;12(7):
pubmed: 35888749
Diabetes. 2010 Feb;59(2):347-57
pubmed: 19934001
Acta Gastroenterol Belg. 2018 Jan-Mar;81(1):55-81
pubmed: 29562379
J Nutr. 2020 May 1;150(5):1076-1085
pubmed: 31919514
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
Hepatology. 2014 Sep;60(3):1113-4
pubmed: 24452327
Nat Med. 2012 Aug;18(8):1279-85
pubmed: 22842477
J Clin Invest. 2000 Apr;105(8):1067-75
pubmed: 10772651
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18273-7
pubmed: 17114290
Hepatology. 2010 Feb;51(2):721-2; author reply 722
pubmed: 20101758
J Clin Endocrinol Metab. 2002 Jul;87(7):3023-8
pubmed: 12107194
Lipids Health Dis. 2018 Dec 22;17(1):291
pubmed: 30579336
FASEB J. 2011 Dec;25(12):4301-11
pubmed: 21873555
Hepatology. 2014 Apr;59(4):1393-405
pubmed: 24254368
Cells. 2022 Aug 31;11(17):
pubmed: 36078124
J Nutr. 2021 Jun 1;151(6):1507-1516
pubmed: 33693866
Acta Gastroenterol Belg. 2020 Oct-Dec;83(4):513-515
pubmed: 33321005
Biochem Biophys Res Commun. 2006 Nov 17;350(2):437-43
pubmed: 17011519
Diabetes. 2002 Aug;51(8):2450-8
pubmed: 12145157
Clin Sci (Lond). 2013 Oct;125(8):391-400
pubmed: 23627434
Metabolism. 2011 Feb;60(2):265-71
pubmed: 20199782
Diabetes. 2013 Jan;62(1):49-55
pubmed: 22923470
J Clin Endocrinol Metab. 2008 Jul;93(7):2702-8
pubmed: 18430773
Diabetes. 2005 Mar;54(3):603-8
pubmed: 15734833
Best Pract Res Clin Gastroenterol. 2014 Aug;28(4):545-58
pubmed: 25194174
Clin Sci (Lond). 2020 Aug 28;134(16):2117-2135
pubmed: 32820802
J Endocrinol Invest. 2021 Jan;44(1):105-110
pubmed: 32350824
World J Hepatol. 2015 Sep 8;7(19):2184-8
pubmed: 26380042
Cell Metab. 2010 Nov 3;12(5):483-95
pubmed: 21035759
Nat Rev Endocrinol. 2017 Sep;13(9):509-520
pubmed: 28621339
Lancet Diabetes Endocrinol. 2022 Apr;10(4):284-296
pubmed: 35183303
Am J Physiol Gastrointest Liver Physiol. 2010 Jan;298(1):G107-16
pubmed: 19875703
J Physiol. 2009 May 15;587(Pt 10):2387-97
pubmed: 19332493
J Biol Chem. 2004 Jul 30;279(31):32345-53
pubmed: 15166226
Metabolites. 2021 Mar 08;11(3):
pubmed: 33800465

Auteurs

Nicolas Lanthier (N)

Laboratory of Gastroenterology and Hepatology, Institut de Recherche Expérimentale et Clinique, UCLouvain, 1200 Brussels, Belgium.
Service d'Hépato-Gastroentérologie, Cliniques universitaires Saint-Luc, UCLouvain, 1200 Brussels, Belgium.

Valérie Lebrun (V)

Laboratory of Gastroenterology and Hepatology, Institut de Recherche Expérimentale et Clinique, UCLouvain, 1200 Brussels, Belgium.

Olivier Molendi-Coste (O)

Laboratory of Gastroenterology and Hepatology, Institut de Recherche Expérimentale et Clinique, UCLouvain, 1200 Brussels, Belgium.

Nico van Rooijen (N)

Department of Molecular Cell Biology, Vrije Universiteit Medical Center, 1081 Amsterdam, The Netherlands.

Isabelle A Leclercq (IA)

Laboratory of Gastroenterology and Hepatology, Institut de Recherche Expérimentale et Clinique, UCLouvain, 1200 Brussels, Belgium.

Classifications MeSH